Judd W. Moul, MD | Authors

Oncology Peer Review On-The-Go: Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

May 30, 2022

Judd W. Moul, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the treatment of a patients with evidence of prostate cancer despite multiple negative prognostic tests.

Successful Diagnosis and Treatment of Occult Prostate Cancer Despite Multiple Negative Prostate Biopsies and Negative Prostate MRIs

March 14, 2022

Dr. Judd W. Moul, MD, and colleagues present the case of a man, aged 73 years, with a prostate-specific antigen level of 110 ng/mL after 4 negative prostate biopsies and 4 negative prostate MRIs.

Judd Moul, MD, Reviews Studies From 2021 ASCO Showing Systemic Therapy Advancements in Prostate Cancer

July 29, 2021

Judd Moul, MD, discusses the gravity of new data on systemic therapies for men with castration-resistant prostate cancer and how they can be of use during the COVID-19 pandemic.

Follow-Up After Negative Bone/CT in Prostate Cancer With Molecular Recurrence 

May 06, 2021

Dr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence. 

Molecular Recurrence in Oligometastatic Prostate Cancer

May 06, 2021

An expert panel discusses the challenges of detecting and managing biochemical recurrence in the context of oligometastatic prostate cancer. 

Sensitivity of Imaging Modalities to Biochemical Recurrence in Prostate Cancer 

May 06, 2021

Dr Munir Ghesani reviews and comments on data regarding the sensitivity of imaging modalities in detecting biochemical recurrence in prostate cancer. 

Case 2: 64-Year-Old Man With Multifocal Prostate Cancer Post-IMRT

April 29, 2021

Dr Raoul Concepcion leads a panel discussion on a case of a 64-year-old man with multifocal prostate cancer treated with IMRT who refused ADT. 

Considerations for Tracer Selection to Assess Biochemical Recurrence in Prostate Cancer 

April 29, 2021

Munir Ghesani, MD, an expert in nuclear medicine, describes the factors that differentiate available tracers and provides guidance on tracer selection. 

Imaging Modalities for Evaluating Biochemical Recurrence in Prostate Cancer 

April 22, 2021

An expert panel reacts to polling data on choice of imaging modalities for patients with prostate patients after definitive therapy and share their insights about best practices.  

Case 1: 58-Year-Old Man 6 Months Post-Radical Prostatectomy 

April 22, 2021

Raoul Concepcion, MD, presents the case of a 58-year-old man who had a radical prostatectomy 6 months prior and discusses how aspects of the case influence treatment selection.